中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 37 Issue 9
Sep.  2021
Turn off MathJax
Article Contents
Article Navigation >  Journal of Clinical Hepatology  > 2021  >  37(9): 2025-2029

Theoretical basis and clinical significance of treating primary liver cancer from the perspective of "regulating and protecting Zhongzhou" in the spleen and stomach

DOI: 10.3969/j.issn.1001-5256.2021.09.005

  • Clinical Research Laboratory of Integrated Traditional Chinese and Western Medicine, Affiliated Hospital of Integrated Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine, Nanjing 210028, China

  • Received Date: 2021-05-14
  • Accepted Date: 2021-05-14
  • Published Date: 2021-09-20
    Abstract
  • This article analyzes and discusses the theoretical basis and clinical significance of the treatment of primary liver cancer (PLC) from the perspective of "regulating and protecting Zhongzhou" in the spleen and stomach. The development and progression of PLC is associated with the damage of "Zhongzhou" in the spleen and stomach caused by various factors, and "ignoring Zhongzhou" and dysfunction of spleen and stomach are the important pathological mechanism of PLC, while strengthening the spleen and stomach and "caring for Zhongzhou" are important measures to strengthen vital Qi and fight against cancer. With reference to the research findings of modern studies, this article elaborates on the antitumor pharmacological effect of compound spleen/stomach-regulating prescription and related traditional Chinese medicine (TCM) drugs in improving immunity and inhibiting tumor cell proliferation, and clinical research findings further confirm the objective therapeutic efficacy and advantages of TCM drugs and prescriptions for strengthening the spleen and stomach and "caring for Zhongzhou" in the treatment of PLC. It is believed that during the syndrome differentiation and treatment of PLC, the acquired foundation of the spleen and stomach should be taken seriously, and it is necessary to "take care of Zhongzhou" and apply TCM drugs and prescriptions for strengthening the spleen, benefiting Qi, and strengthening the spleen and stomach, so as to improve overall clinical outcome.

     

    • FullText(HTML)
  • loading
    • References(29)
  • [1]
    Chinese Society of Hepatology, Chinese Medical Association. Consensus on the secondary prevention for primary liver cancer (2021 edition)[J]. J Clin Hepatol, 2021, 37(3): 532-542. DOI: 10.3969/j.issn.1001-5256.2021.03.008.

    中华医学会肝病学分会. 原发性肝癌二级预防共识(2021年版)[J]. 临床肝胆病杂志, 2021, 37(3): 532-542. DOI: 10.3969/j.issn.1001-5256.2021.03.008.
    [2]
    BRAY F, FERLAY J, SOERJOMATARAM I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018, 68(6): 394-424. DOI: 10.3322/caac.21492.
    [3]
    FENG RM, ZONG YN, CAO SM, et al. Current cancer situation in China: Good or bad news from the 2018 Global Cancer Statistics?[J]. Cancer Commun (Lond), 2019, 39(1): 22. DOI: 10.1186/s40880-019-0368-6.
    [4]
    National Health and Family Planning Commission of the People's Republic of China. Diagnosis, management, and treatment of hepatocellular carcinoma (V2017)[J]. J Clin Hepatol, 2017, 33(8): 1419-1431. DOI: 10.3969/j.issn.1001-5256.2017.08.003.

    中华人民共和国国家卫生和计划生育委员会. 原发性肝癌诊疗规范(2017年版)[J]. 临床肝胆病杂志, 2017, 33(8): 1419-1431. DOI: 10.3969/j.issn.1001-5256.2017.08.003.
    [5]
    LI YJ. Diagnosis, treatment, and medication rules of articles on traditional Chinese medicine in treatment of liver cancer[D]. Nanjing: Nanjing University of Chinese Medicine, 2010.

    李有骏. 中医药治疗肝癌相关文献的证治用药之规律研究[D]. 南京: 南京中医药大学, 2010.
    [6]
    LIN LZ, XIAO ZW, HUANG XW, et al. Review of practice of diagnosis and treatment for primary liver cancer with integrated traditional Chinese and Western medicine[J]. J Oncol Chin Med, 2020, 2(1): 5-9. DOI: 10.19811/j.cnki.ISSN2096-6628.2020.01.002.

    林丽珠, 肖志伟, 黄学武, 等. 原发性肝癌中西医结合诊疗实践回眸[J]. 中医肿瘤学杂志, 2020, 2(1): 5-9. DOI: 10.19811/j.cnki.ISSN2096-6628.2020.01.002.
    [7]
    BOUTRON MC, FAIVRE J, MILAN C, et al. Primary liver cancer in Côte d'Or (France)[J]. Int J Epidemiol, 1988, 17(1): 21-26. DOI: 10.1093/ije/17.1.21.
    [8]
    ZHAO DG, YE LH. Research progress of Chinese medicine on primary liver cancer[J]. J Liaoning Univ Tradit Chin Med, 2011, 13(12): 207-209. https://www.cnki.com.cn/Article/CJFDTOTAL-LZXB201112095.htm

    赵冬耕, 叶丽红. 肝癌中医研究近况[J]. 辽宁中医药大学学报, 2011, 13(12): 207-209. https://www.cnki.com.cn/Article/CJFDTOTAL-LZXB201112095.htm
    [9]
    CHEN YQ. Etiology and pathogenesis of primary liver cancer and related principles and methods of treatment[D]. Wuhan: Hubei University of Chinese Medicine, 2005.

    陈月雀. 原发性肝癌的病因病机及治则治法探讨[D]. 武汉: 湖北中医学院, 2005.
    [10]
    WANG S. Distribution of traditional Chinese medicine syndrome types of primary liver cancer and their association with laboratory markers[D]. Changchun: Changchun University of Chinese Medicine, 2020.

    王松. 原发性肝癌中医证型分布规律及其相关性研究[D]. 长春: 长春中医药大学, 2020.
    [11]
    ZHUANG TZ, CHEN YB, AN HY. Discussion on TCM syndrome differentiation of primary liver cancer[J]. Forum Tradit Chin Med, 2021, 36(1): 18-19. https://www.cnki.com.cn/Article/CJFDTOTAL-GYLT202101009.htm

    庄桐粧, 陈钰冰, 安海燕. 原发性肝癌中医辨证探讨[J]. 国医论坛, 2021, 36(1): 18-19. https://www.cnki.com.cn/Article/CJFDTOTAL-GYLT202101009.htm
    [12]
    PAN SM, ZHANG XY, WU DY, et al. Analysis of medication rules of TCM prescription against primary hepatic carcinoma based on TCM data analysis platform based on strategy pattern[J]. China Pharm, 2020, 31(24): 2966-2973. DOI: 10.6039/j.issn.1001-0408.2020.24.04.

    潘树茂, 章新友, 吴地尧, 等. 基于中药数据策略模式分析平台分析治疗原发性肝癌中药处方的用药规律[J]. 中国药房, 2020, 31(24): 2966-2973. DOI: 10.6039/j.issn.1001-0408.2020.24.04.
    [13]
    CHEN QL, TANG DX, LONG FX. Research advances in traditional Chinese medicine in treatment of liver cancer[J]. J Guiyang Coll Tradit Chin Med, 2016, 38(2): 99-100. DOI: 10.16588/j.cnki.issn.1002-1108.2016.02.029.

    陈启亮, 唐东昕, 龙奉玺. 中医药对肝癌治疗的研究进展[J]. 贵阳中医学院学报, 2016, 38(2): 99-100. DOI: 10.16588/j.cnki.issn.1002-1108.2016.02.029.
    [14]
    ZHU GH, TIAN QH, DAI MH, et al. Medication features and key strategies for traditional Chinese medicine intervention of primary liver cancer[J]. Liaoning J Tradit Chin Med, 2020, 47(7): 37-41. DOI: 10.13192/j.issn.1000-1719.2020.07.008.

    朱广辉, 田启航, 戴明昊, 等. 中医药干预原发性肝癌的用药特点及关键策略思考[J]. 辽宁中医杂志, 2020, 47(7): 37-41. DOI: 10.13192/j.issn.1000-1719.2020.07.008.
    [15]
    CHEN QL, TANG DX, LONG FX. The five elements theory, when the liver is affected, a prescription is chosen to replenish the spleen, applies in the liver cancer prevention and treatment[J]. China J Chin Med, 2016, 31(12): 1833-1835. DOI: 10.16368/j.issn.1674-8999.2016.12.511.

    陈启亮, 唐东昕, 龙奉玺. "见肝之病, 知肝传脾"在肝癌防治中的运用[J]. 中医学报, 2016, 31(12): 1833-1835. DOI: 10.16368/j.issn.1674-8999.2016.12.511.
    [16]
    PENG HY, ZHANG J, YOU X, et al. On Therapeutic methods of primary hepatic carcinoma[J]. J Nangjing Univ Tradit Chin Med, 2014, 30(3): 203-206. https://www.cnki.com.cn/Article/CJFDTOTAL-NJZY201403002.htm

    彭海燕, 张静, 尤夏, 等. 原发性肝癌治法探讨[J]. 南京中医药大学学报, 2014, 30(3): 203-206. https://www.cnki.com.cn/Article/CJFDTOTAL-NJZY201403002.htm
    [17]
    CHEN WZ, XU TT, ZHU FS, et al. Effect of Yiqi Jianpi Huaji Fang on quality of life in gastric cancer patients with chemotherapy of qi deficiency and blood stasis type: A double-blind randomized placebo-controlled trial[J]. J Tradit Chin Med, 2017, 58(9): 759-762. DOI: 10.13288/j.11-2166/r.2017.09.011.

    陈婉珍, 徐婷婷, 朱方石, 等. 益气健脾化积方对胃癌化疗气虚血瘀证患者生活质量影响的随机双盲安慰剂对照试验[J]. 中医杂志, 2017, 58(9): 759-762. DOI: 10.13288/j.11-2166/r.2017.09.011.
    [18]
    YE JY, AN ZT, CHEN WZ, et al. Discussion on the theoretical mechanism for regulating immune in patients with gastric cancer of replenishing qi to invigorate the spleen and relieve stasis decoction[J]. J Zhejiang Univ Tradit Chin Med, 2017, 41(6): 499-501. DOI: 10.16466/j.issn.1005-5509.2017.06.012.

    叶昀旖, 安振涛, 陈婉珍, 等. 益气健脾化积方对胃癌患者免疫功能调节作用的理论机制探讨[J]. 浙江中医药大学学报, 2017, 41(6): 499-501. DOI: 10.16466/j.issn.1005-5509.2017.06.012.
    [19]
    LIU MB. Effect of Xiangsha Liujunzi decoction on immune function and gut microecology in patients with spleen-deficiency diarrhea[D]. Suzhou: Soochow University, 2015.

    刘名波. 香砂六君子汤对脾虚泄泻免疫功能和肠道微生态的影响[D]. 苏州: 苏州大学, 2015.
    [20]
    LI L. Effect of Astragalus membranaceus in improving efficacy and reducing toxicity in tumor chemotherapy[J]. Pract Tradit Chin Intern Med, 2007, 21(1): 27-29. DOI: 10.3969/j.issn.1671-7813.2007.01.015.

    李黎. 黄芪在肿瘤化疗中的增效减毒作用[J]. 实用中医内科杂志, 2007, 21 (1): 27-29. DOI: 10.3969/j.issn.1671-7813.2007.01.015.
    [21]
    LI D, LI ZL. The Research status of that codonopsis pilosula polysaccharide is as an immune adjuvant[J]. Guide China Med, 2013, 11(28): 56-57. DOI: 10.3969/j.issn.1671-8194.2013.28.034.

    李达, 李在林. 党参多糖作为免疫佐剂的研究综述[J]. 中国医药指南, 2013, 11(28): 56-57. DOI: 10.3969/j.issn.1671-8194.2013.28.034.
    [22]
    SUN WP, LI FS, CHEN C, et al. Immunomodulation of atractylodis polysaccharides in mice[J]. Chin J Microecol, 2011, 23(10): 881-882, 886. https://www.cnki.com.cn/Article/CJFDTOTAL-ZGWS201110004.htm

    孙文平, 李发胜, 陈晨, 等. 白术多糖对小鼠免疫功能调节的研究[J]. 中国微生态学杂志, 2011, 23(10): 881-882, 886. https://www.cnki.com.cn/Article/CJFDTOTAL-ZGWS201110004.htm
    [23]
    YE LH, CHENG HB, ZHANG YH, et al. Treatment principle and methods of Chinese medicine for primary liver cancer[J]. J Nangjing Univ Tradit Chin Med, 2010, 26(1): 10-13. DOI: 10.3969/j.issn.1000-5005.2010.01.003.

    叶丽红, 程海波, 章永红, 等. 原发性肝癌的中医治则与治法探讨[J]. 南京中医药大学学报, 2010, 26(1): 10-13. DOI: 10.3969/j.issn.1000-5005.2010.01.003.
    [24]
    ZHANG Y, CHEN HG, ZHAO C, et al. Research progress on anti-hepatocellular carcinoma mechanism of active ingredients of traditional Chinese medicine[J]. China J Chin Mater Med, 2020, 45(14): 3395-3406. DOI: 10.19540/j.cnki.cjcmm.20200429.601

    张宇, 陈华国, 赵超, 等. 中药有效成分抗肝癌作用机制研究进展[J]. 中国中药杂志, 2020, 45(14): 3395-3406. DOI: 10.19540/j.cnki.cjcmm.20200429.601.
    [25]
    YANG X, LIU YG, CHANG ZJ. Professor Chang Zhanjie's experience in the application of Buzhong Yiqi decoction in treatment of pyrexia in liver cancer[J]. Mod Tradit Chin Med, 2016, 36(4): 1-3. DOI: 10.13424/j.cnki.mtcm.2016.04.001.

    杨璇, 刘永刚, 常占杰. 常占杰教授运用补中益气汤治疗肝癌发热经验[J]. 现代中医药, 2016, 36(4): 1-3. DOI: 10.13424/j.cnki.mtcm.2016.04.001.
    [26]
    WANG JS, CHEN LY, LIU YQ, et al. Professor SUN Guizhi's experience in treating liver cancer from Tonifying the spleen and stomach, and preventive treatment of disease[J]. J Tradit Chin Med, 2015, 56(13): 1096-1098. DOI: 10.13288/j.11-2166/r.2015.13.005.

    王靖思, 陈兰羽, 刘玉琴, 等. 孙桂芝从补脾胃、治未病论治肝癌经验[J]. 中医杂志, 2015, 56(13): 1096-1098. DOI: 10.13288/j.11-2166/r.2015.13.005.
    [27]
    HUANG ZB, HUANG ZM, CHEN GQ. Clinical effect of spleen-strengthening, stasis-resolving, and detoxicating therapy in treatment of advanced primary liver cancer: An analysis of 36 cases[J]. J New Chin Med, 2011, 43(5): 54-56. https://www.cnki.com.cn/Article/CJFDTOTAL-REND201105027.htm

    黄振步, 黄兆明, 陈光群. 健脾化瘀解毒法治疗晚期原发性肝癌36例疗效观察[J]. 新中医, 2011, 43(5): 54-56. https://www.cnki.com.cn/Article/CJFDTOTAL-REND201105027.htm
    [28]
    ZHANG H, FANG ZQ. Progress in clinical study on methods of strengthening the spleen and promoting qi for preventing and treating liver cancer[J]. Henan Tradit Chin Med, 2007, 27(7): 78-81. DOI: 10.3969/j.issn.1003-5028.2007.07.064.

    张辉, 方肇勤. 健脾理气法应用于肝癌的临床进展[J]. 河南中医, 2007, 27(7): 78-81. DOI: 10.3969/j.issn.1003-5028.2007.07.064.
    [29]
    ZHONG C, LI HD, LIU DY, et al. Clinical study of hepatectomy combined with Jianpi Huayu Therapy for hepatocellular carcinoma[J]. Asian Pac J Cancer Prev, 2014, 15(14): 5951-5957. DOI: 10.7314/apjcp.2014.15.14.5951.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索
    Get Citation
    PDF
    XML

    Article Metrics

    Article views (519) PDF downloads(43) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[]YesterdayPV[]TodayIP[]TodayPV[]Online[]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return